Norepinephrine antagonists and cancer risk

Int J Cancer. 2011 Feb 1;128(3):737-8; author reply 739. doi: 10.1002/ijc.25351.
No abstract available

Publication types

  • Comment
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Atenolol / adverse effects
  • Breast Neoplasms / epidemiology
  • Clonidine / adverse effects
  • Colonic Neoplasms / epidemiology
  • Female
  • Humans
  • Lung Neoplasms / epidemiology
  • Male
  • Metoprolol / adverse effects
  • Neoplasms / epidemiology*
  • Norepinephrine / adverse effects
  • Norepinephrine / antagonists & inhibitors*
  • Odds Ratio
  • Prazosin / adverse effects
  • Prazosin / analogs & derivatives
  • Propranolol / adverse effects
  • Prostatic Neoplasms / epidemiology
  • Risk Assessment

Substances

  • Atenolol
  • Terazosin
  • Propranolol
  • Metoprolol
  • Clonidine
  • Norepinephrine
  • Prazosin